When was Alnylam founded?

Alnylam was founded in 2002 and raised its 1st funding round within a year of its incorporation.

Where is Alnylam located?

Alnylam is headquartered in Cambridge, United States.

Who is the current CEO of Alnylam?

John Maraganore of Alnylam. They are also angel investors in 6 startups, including .

How many employees does Alnylam have?

As of Jul 31, 2026, the latest employee count at Alnylam is 2984.

Is Alnylam a funded company?

Alnylam is a funded company, having raised a total of $17M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 01, 2002.

When was the latest funding round of Alnylam?

Alnylam's latest funding was a $***** Post IPO round on Aug 17, 2020, with participation from 1 investor. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.1B in funding in 2026 to date.

What is the annual revenue of Alnylam?

Annual revenue of Alnylam is more than $1B as on Dec 31, 2024

Where does Alnylam rank among its competitors?

Alnylam ranks 2nd amongst 841 active competitors, of which 288 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Nanopore Technologies, which secured $102M in Aug, 2024.

Who are the top competitors of Alnylam?

Alnylam's top competitors include BridgeBio, PTC Therapeutics and Nanopore Technologies. Among them, Nanopore Technologies secured the most recent funding round in August, 2024.

Alnylam - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of RNA interference-based therapeutics for multiple disorders. Its pipeline includes drugs that are used to treat hereditary ATTR Amyloidosis, acute hepatic porphyria, and treating hypercholesterolemia. It also develops drugs for cardiometabolic diseases, infectious diseases, central nervous system, and ocular diseases.

Website: www.alnylam.com/
Social

Key Metrics

Founded Year

2002

Location

Cambridge, United States

Stage

Public

Total Funding

$17M in 7 rounds

Latest Funding Round

Post IPO, Aug 17, 2020, $*****

Investors

Colt Ventures & 14 more

Ranked

2^nd among 841 active competitors

Annual Revenue

$1B+ as on Dec 31, 2024

Employee Count

2,984 as on Jul 31, 2026

Investment & Acquisitions

Sirna Therapeutics & 3 more

Similar Companies

BridgeBio & 1014 more

Exit Details

Public

View Alnylam's full profile

Alnylam is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Alnylam Pharmaceuticals, Inc. CIN: 1178670 , United States, Active	May 07, 2003	$1B+ (As on Dec 31, 2024)	2100 (As on Dec 31, 2023)	-

Alnylam got listed on May 28, 2004.

Click here to take a look at Alnylam's IPO in detail

Alnylam has raised a total funding of $17M over 7 rounds. Its first funding round was on Aug 01, 2002. Its latest funding round was a Post IPO round on Aug 17, 2020 for $*****. 1 investor participated in its latest round. Alnylam has 15 institutional investors.

Here is the list of recent funding rounds of Alnylam:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 17, 2020	8151762	Post IPO	9359176	9144535	3152949	6995619
Apr 13, 2020	3138284	Post IPO	4415708	6783337	3586805	Blackstone
Nov 15, 2017	1697297	Post IPO	3714462	9262841	4481374	7334572

Access funding benchmarks and valuations. Sign up today!

View details of Alnylam's funding rounds and investors

The founders of Alnylam are John Clarke, Paul Schimmel and Phillip Sharp. John Maraganore is the CEO of Alnylam.

Here are the details of Alnylam's key team members:

John Clarke: Co-Founder of Alnylam and founder of 1 other company. They are also an angel investor in 1 startup and serve on the board of 1 company.
Paul Schimmel: Co-Founder of Alnylam and founder of 2 other companies, Alnylam and OXLUMO.
Phillip Sharp: Co-Founder of Alnylam and founder of 1 other company.
John Maraganore: CEO of Alnylam. They are also an angel investor in 6 startups.
Contact Info: 1 email address

View details of Alnylam's Founder profiles and Board Members

Alnylam's employee count trend

Alnylam has 2,984 employees as of Jul 26. Here is Alnylam's employee count trend over the years:

Uncover Alnylam's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alnylam include BridgeBio, PTC Therapeutics and Nanopore Technologies. Here is the list of Top 10 competitors of Alnylam, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Nanopore Technologies 2005, Oxford (United Kingdom), Public	Manufacturer of portable and benchtop devices for real-time DNA sequencing	$1.34B	IP Group, GIC & 93 others	75/100
5th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
8th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
9th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
10th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Alnylam's competitors? Click here to see the top ones

Alnylam has made 2 investments in companies including Regulus Therapeutics and Arbutus Bio. Alnylam has also acquired 2 companies including Sirna Therapeutics and Nucleonics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 12, 2014	Acquisition	Sirna Therapeutics	1992	San Francisco (United States)
Mar 03, 2009	Investments	Regulus Therapeutics	2007	San Diego (United States)
Dec 08, 2008	Acquisition	Nucleonics	2001	Langhorne (United States)